The estimated Net Worth of Robert Bowen is at least $30.9 Million dollars as of 15 May 2015. Robert Bowen owns over 6,222 units of Abiomed stock worth over $29,058,490 and over the last 16 years Robert sold ABMD stock worth over $1,868,943.
Sign up
Robert Bowen ABMD stock SEC Form 4 insiders trading
Robert has made over 17 trades of the Abiomed stock since 2011, according to the Form 4 filled with the SEC. Most recently Robert sold 6,222 units of ABMD stock worth $421,354 on 15 May 2015.
The largest trade Robert's ever made was exercising 40,786 units of Abiomed stock on 15 July 2013 worth over $239,006. On average, Robert trades about 5,641 units every 50 days since 2008. As of 15 May 2015 Robert still owns at least 76,265 units of Abiomed stock.
You can see the complete history of Robert Bowen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Robert Bowen's mailing address?
Robert's mailing address filed with the SEC is C/O ABIOMED, INC, 22 CHERRY HILL DR, DANVERS, MA, 01923.
Insiders trading at Abiomed
Over the last 22 years, insiders at Abiomed have traded over $148,507,587 worth of Abiomed stock and bought 232,354 units worth $4,276,073 . The most active insiders traders include Michael R Minogue, Eric A Md Rose, and David M Weber. On average, Abiomed executives and independent directors trade stock every 16 days with the average trade being worth of $5,341,900. The most recent stock trade was executed by Martin P Sutter on 17 February 2022, trading 4,000 units of ABMD stock currently worth $1,258,840.
What does Abiomed do?
Abiomed Europe GmbH, Aachen / Germany, as affiliate of Abiomed Inc. headquartered in Danvers, Massachusetts, USA, is a leading medical technology company in the field of circulatory support. Its products aim to enable heart recovery by improving blood circulation and/or heart pump function.
What does Abiomed's logo look like?
Complete history of Robert Bowen stock trades at Abiomed
Abiomed executives and stock owners
Abiomed executives and other stock owners filed with the SEC include:
-
Michael Minogue,
Chairman of the Board, President, Chief Executive Officer -
Todd Trapp,
Chief Financial Officer, Vice President -
Andrew Greenfield,
Vice President, Chief Commercial Officer -
David Weber,
Chief Operating Officer, Senior Vice President -
Michael R. Minogue,
Chairman, CEO & Pres -
Michael Howley,
Vice President and General Manager, Global Sales -
Todd A. Trapp,
CFO & VP -
Dr. David M. Weber,
Sr. VP & COO -
Marc A. Began,
VP, Gen. Counsel & Sec. -
Andrew J. Greenfield,
VP & Chief Commercial Officer -
Dorothy Puhy,
Lead Independent Director -
Paul Thomas,
Independent Director -
Martin Sutter,
Independent Director -
Jeannine Rivet,
Independent Director -
Christopher Van Gorder,
Independent Director -
Eric Rose,
Independent Director -
Marc Began,
Vice President, General Counsel, Secretary -
Karen Mahoney,
Head of Global HR -
Michael G. Howley,
VP & GM of Global Sales -
Sarah Karr,
Communications Mang. -
Ingrid Goldberg Ward,
Director of Investor Relations -
Dr. Thorsten Siess Ph.D.,
VP & CTO -
Henri A Termeer,
Director -
Gorder Chris Van,
Director -
William J Bolt,
SVP, DA and QA -
Michael John Tomsicek,
Vice President, CFO -
W Gerald Austen,
Director -
Myron L Rolle,
Director -
Louis E Lataif,
Director -
Robert Bowen,
Chief Financial Officer -
Ronald W Dollens,
Director -
Daniel J Sutherby,
CFO -
Inc Abiomed,
Director -
Connell Desmond Jr O,
Director -
Paul Fireman,
Director -
Javier Jimenez,
VP Operations -
Anthony W Bailey,
VP, Business Development -
David M Lederman,
Chairman, CEO & President -
Charles B Haaser,
Principal Financial Officer -
Eugene D Rabe,
SVP, Global Sales & Services -
Christopher D Macdonald,
SVP Global Sales -
Sheila Marie Flaherty,
VP, General Counsel -
Robert T V Kung,
SVP, Chief Scientific Officer -
Edward E Berger,
VP, Strat. Plan & Ext. Comm. -
Patricia A. Fitch,
Vice President of Sales -
Raymond J Kelley,
VP Marketing -
David Gottlieb,
Director -
John F Obrien,
Director -
Gary Stickel,
VP of HR -
Karim Benali,
VP Product Development -
Robert Farra,
VP Engineering & Manufacturing -
Stephen C Mc Evoy,
VP and General Counsel -
Paula A Johnson,
Director